Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.71 Consensus Price Target from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $43.71.

Several research analysts have commented on the stock. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Finally, Chardan Capital reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th.

Insider Activity

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the business’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the transaction, the chief executive officer now owns 3,921,255 shares in the company, valued at $45,055,219.95. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ARWR. Focus Partners Wealth lifted its stake in shares of Arrowhead Pharmaceuticals by 1,339.5% in the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 15,123 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after buying an additional 2,774,933 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 979 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the period. Finally, Dynamic Technology Lab Private Ltd increased its stake in shares of Arrowhead Pharmaceuticals by 40.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company’s stock worth $343,000 after acquiring an additional 7,827 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $15.70 on Tuesday. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $30.41. The company has a fifty day moving average of $14.37 and a 200-day moving average of $17.06. The company has a market capitalization of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.96. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts’ expectations of $116.27 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share. As a group, equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.